A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs P28 peptide (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CDG Therapeutics
- 07 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Interim results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
- 24 May 2011 Status changed from recruiting to completed.